Free Trial
NASDAQ:FBRX

Forte Biosciences (FBRX) Stock Price, News & Analysis

Forte Biosciences logo
$7.35 -0.08 (-1.08%)
Closing price 04/2/2025 04:00 PM Eastern
Extended Trading
$7.02 -0.32 (-4.42%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Forte Biosciences Stock (NASDAQ:FBRX)

Key Stats

Today's Range
$7.21
$7.98
50-Day Range
$5.50
$15.96
52-Week Range
$4.11
$28.68
Volume
13,337 shs
Average Volume
149,333 shs
Market Capitalization
$46.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.58
Consensus Rating
Buy

Company Overview

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Remove Ads

Forte Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
59th Percentile Overall Score

FBRX MarketRank™: 

Forte Biosciences scored higher than 59% of companies evaluated by MarketBeat, and ranked 427th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Forte Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Forte Biosciences has only been the subject of 2 research reports in the past 90 days.

  • Read more about Forte Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Forte Biosciences are expected to grow in the coming year, from ($12.12) to ($3.68) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Forte Biosciences is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Forte Biosciences is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Forte Biosciences has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Forte Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    0.26% of the float of Forte Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Forte Biosciences has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Forte Biosciences has recently increased by 9.60%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Forte Biosciences does not currently pay a dividend.

  • Dividend Growth

    Forte Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.26% of the float of Forte Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Forte Biosciences has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Forte Biosciences has recently increased by 9.60%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Forte Biosciences has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Forte Biosciences this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    3 people have added Forte Biosciences to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Forte Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.10% of the stock of Forte Biosciences is held by insiders.

  • Percentage Held by Institutions

    77.63% of the stock of Forte Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Forte Biosciences' insider trading history.
Receive FBRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Forte Biosciences and its competitors with MarketBeat's FREE daily newsletter.

FBRX Stock News Headlines

Forte Biosciences price target lowered to $61 from $64 at Chardan
Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Forte Biosciences (FBRX) Gets a Buy from TD Cowen
Forte Biosciences files $300M mixed securities shelf
See More Headlines

FBRX Stock Analysis - Frequently Asked Questions

Forte Biosciences' stock was trading at $22.71 at the beginning of 2025. Since then, FBRX stock has decreased by 67.6% and is now trading at $7.35.
View the best growth stocks for 2025 here
.

Forte Biosciences, Inc. (NASDAQ:FBRX) released its earnings results on Wednesday, August, 14th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.16) by $0.11.

Shares of FBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Forte Biosciences investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), PayPal (PYPL), QUALCOMM (QCOM), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM) and Meta Platforms (META).

Company Calendar

Last Earnings
8/14/2024
Today
4/03/2025
Next Earnings (Estimated)
5/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:FBRX
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$22.58
High Stock Price Target
$61.00
Low Stock Price Target
$2.75
Potential Upside/Downside
+207.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-31,480,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$24.30 per share
Price / Book
0.30

Miscellaneous

Free Float
6,195,000
Market Cap
$46.99 million
Optionable
Optionable
Beta
2.35
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report

This page (NASDAQ:FBRX) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners